stem cell transplant

Clinical trial evaluates blood stem cell transplantation for patients with T-cell disorders

Oct 2, 2018

T cells, a type of white blood cell, develop from stem cells, mature in the thymus gland and play a key role in human immunity by protecting the body from infection. They may also help to fight cancer. People whose T cells fail to properly develop or function can develop imbalances in the immune system that lead to cancer, autoimmune disease and other problems. Jennifer Kanakry, M.D., of the Experimental Transplantation and Immunology Branch is leading a study that transplants allogeneic blood-forming stem cells from healthy donors into patients with T-cell disorders. Read more...

Mai in Afghanistan receiving the Bronze Star from Lieutenant General Michael Williamson

Former world-class hammer thrower battles diffuse large B-cell lymphoma (DLBCL)

Sep 28, 2018

In August of 2013, eight months into his volunteer deployment in Afghanistan, Michael Mai noticed a small lump between his neck and shoulder. The former world-class hammer thrower initially brushed it off as nothing but was later diagnosed with diffuse large B-cell lymphoma (DLBCL). Mai came to NIH and received treatment from Mark Roschewski, M.D., Clinical Director of the Lymphoid Malignancies Branch, that ultimately cleared him of the disease. Read more...

Multiple myeloma

Early-phase clinical trial to test new CAR T-cell therapy for multiple myeloma

Sep 18, 2018

Center for Cancer Research investigators led by James Kochenderfer, M.D., of the Experimental Transplantation and Immunology Branch, are conducting a clinical trial to test a new chimeric antigen receptor (CAR) T-cell therapy in patients whose multiple myeloma has persisted or relapsed despite standard therapy. Their goal is to develop a CAR T-cell therapy that provides lasting remission of a disease that remains highly resistant to current treatments. Read more...

lung cancer cells

Clinical trial tests immunotherapy combination for relapsed small cell lung cancer

Aug 20, 2018

Two anticancer drugs used to treat small cell lung cancer (SCLC) damage the DNA inside cancer cells and block the cells’ ability to grow and multiply, but these responses are usually short lived. A study led by Anish Thomas, M.D., of the Developmental Therapeutics Branch is using these drugs in combination with another drug called M7824 to treat relapsed SCLC. The trial aims to see if the drugs complement each other by helping the immune system kill more SCLC cells. Read more...

Mesothelioma microenvironment

Clinical trial studies benefit of targeted drug for malignant mesothelioma

Jul 11, 2018

Malignant mesothelioma is cancer that begins in a layer of specialized cells called the mesothelium that line the outer surface of most internal organs. A team led by Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch aims to see if the drug olaparib causes mesothelial tumors to shrink in patients with mutated BAP-1 or other DNA damage-repair genes and in patients with no mutations in these genes.  Read more...

immunotherapy

Clinical trial tests combinations of immunotherapy drugs for prostate cancer

Jun 20, 2018

Metastatic castration-resistant prostate cancer (mCRPC) is a disease that has spread beyond the prostate and no longer responds to hormone therapy. James Gulley, M.D., Ph.D., of the Genitourinary Malignancies Branch is leading a study of combination immunotherapy where patients will be treated with two, three or four drugs that affect the immune system in different ways to determine the safety of various combinations and whether they can make tumors shrink. Read more...

CBS news logo

Steve Rosenberg featured in CBS News story profiling an immunotherapy clinical trial patient

Jun 11, 2018

When standard treatment failed to eliminate her late-stage breast cancer, Judy Perkins turned to a clinical trial led by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the Center for Cancer Research. The trial uses a novel immunotherapy approach of multiplying specific cancer-fighting cells and injecting them into a patient’s bloodstream to kill the cancer. In a recent interview with CBS News’ Jonathan LaPook, Perkins — who remains cancer free more than two years later — shares her clinical trial experience.  Read more...

Steve Rosenberg featured in CBS News story profiling an immunotherapy clinical trial patient
Breast cancer scan

Findings from clinical trial led by Steve Rosenberg published in Nature Medicine

Jun 4, 2018

Findings from a clinical trial led by Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, were recently published in Nature Medicine. The ongoing phase II trial explores a novel approach to immunotherapy that led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. Using a modified form of adoptive cell transfer, investigators aim to target tumor cell mutations to shrink tumors in patients with common epithelial cancers. According to Dr. Rosenberg, “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many cancer types.”  Read more...

Findings from clinical trial led by Steve Rosenberg published in Nature Medicine
Lipogenesis in Prostate Cancer

Combination therapy for biochemically recurrent prostate cancer tested in new trial

May 31, 2018

Prostate-specific antigen (PSA) is an enzyme released by the prostate gland and is found in abnormally high concentrations in the blood of men with prostate cancer. “Biochemical recurrence” is when PSA levels continue to rise after initial treatment for prostate cancer, such as surgery or radiation. Marijo Bilusic, M.D., of the Genitourinary Malignancies Branch is leading the Center for Cancer Research’s effort in a study to treat men with biochemically recurrent prostate cancer with a combination drug therapy. Read more...

Mesothelioma Spheroid

Clinical trial tests drug combination in mesothelioma of the lung or abdomen

May 29, 2018

Mesothelioma is an aggressive form of cancer caused by asbestos with no known cure and a very poor prognosis. Raffit Hassan, M.D., of the Thoracic and GI Malignancies Branch is leading a study to determine a safe dose of a combination drug therapy in patients with advanced mesothelioma.  Read more...

Pages